<h3 style="font-size: 90px;">Now Available in <strong>Canada</strong></h3>

Now Available in Canada

Learn More
<h3 style="font-size: 80px;">THE ESSENTIAL NON-TUMESCENT, NON-THERMAL (NTNT) CHOICE<sup>1</sup></h3>

THE ESSENTIAL NON-TUMESCENT, NON-THERMAL (NTNT) CHOICE1

An endovenous microfoam procedure for GSV-system varicosities of any shape1*

Microfoam Education

What is an ideal microfoam? View More

How effective is Varithena®

Learn more about Varithena® pivotal trials View More

GETTING STARTED

  View More

Contact Us

Enter security code:
 Security code

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

Visit MedEffect Canada, or call 1-866-234-2345 (toll-free) to report side effects.

INDICATIONS 

Varithena® is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the GSV system, above and below the knee.
Varithena® is intended for use in adults with clinically significant venous reflux as diagnosed by duplex ultrasound.

Physicians administering Varithena® must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease, and be trained in the administration of the product.

Contraindications

  • Acute thromboembolic disease
  • Thrombophilia
  • Pregnancy

Anaphylaxis: Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately.

Tissue Ischemia and Necrosis: Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately.

Venous Thrombosis: Varithena® can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Ischemic cerebrovascular events.

Ischemic cerebrovascular events: Ischemic cerebrovascular events such transient ischemic attack (TIA) or stroke have been reported rarely for sclerosing agents minutes or days after sclerotherapy. These events have not been reported to date with Varithena®

Other relevant warnings and precautions

  • Monitoring for post-procedural hypersensitivity and neurological signs
  • Benefit-risk considerations in patients with significant cardiovascular disease
  • Monitoring of ischemic adverse events and counselling in patients with patent foramen ovale (PFO)
  • Avoiding administration in nursing women
  • Use in pediatric patients (<18 years of age) is not recommended
  • Caution in patients with hepatic and renal impairment

For more information

Please consult the product monograph at https://health-products.canada.ca/dpd-bdpp/index-eng.jsp for more information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece.

The product monograph is also available by calling us at 1-844-282-1BTG (1284).

Follow Us